19,456 Shares in Bioventus Inc. (NYSE:BVS) Bought by Centiva Capital LP

Centiva Capital LP acquired a new stake in Bioventus Inc. (NYSE:BVS) in the third quarter, Holdings Channel reports. The institutional investor acquired 19,456 shares of the company’s stock, valued at approximately $232,000.

Other large investors have also modified their holdings of the company. Royce & Associates LP purchased a new position in shares of Bioventus in the 3rd quarter valued at about $8,337,000. Renaissance Technologies LLC increased its position in shares of Bioventus by 401.5% in the second quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock valued at $2,893,000 after buying an additional 402,841 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Bioventus by 38.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after buying an additional 109,359 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Bioventus during the 3rd quarter worth approximately $4,515,000. Finally, Marshall Wace LLP lifted its position in shares of Bioventus by 38.2% during the 2nd quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock valued at $1,911,000 after buying an additional 91,843 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of research analyst reports. Craig Hallum upped their price objective on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group upped their price target on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Bioventus Stock Up 1.4 %

NYSE BVS opened at $11.58 on Thursday. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The business has a fifty day moving average price of $12.11 and a 200 day moving average price of $9.46. The company has a market cap of $939.77 million, a P/E ratio of -18.72 and a beta of 0.79.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same period last year, the firm posted $0.05 earnings per share. Research analysts anticipate that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.